Chiaramonte Rita, Caramma Salvatore, Buccheri Enrico, Finocchiaro Patrizia, Longo Umile Giuseppe, Ammendolia Antonio, de Sire Alessandro, Vecchio Michele
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Department of Pain Management, Policlinico-San Marco Hospital, 95123 Catania, Italy.
J Funct Morphol Kinesiol. 2025 Mar 26;10(2):104. doi: 10.3390/jfmk10020104.
Knee osteoarthritis (OA) is a prevalent condition among adults that leads to knee joint pain and dysfunction. Over the past two decades, local intra-articular knee injection therapy has gained popularity due to the advent of platelet-rich plasma (PRP), hyaluronic acid (HA), and the novel peripheral blood-derived mononuclear cells (PBMNCs). This study aimed to compare the therapeutic efficacy of intra-articular injections of PBMNCs, HA, and PRP combined with hyaluronic acid (PRP-HA) for treating degenerative knee OA classified as stages II and III, according to the Kellgren and Lawrence (KL) scale. This retrospective observational study involved adults with moderate-to-moderately severe knee OA treated at the University Hospital of Catania, Italy. The subjects were divided into three groups and treated with intra-articular injections of HA, PRP-HA, or PBMNCs. The outcome measures assessed were as follows: the Numerical Rating Scale, the Western Ontario and McMaster Universities Arthritis Index, the Timed Up and Go, the International Knee Documentation Committee score, a 10-meter walking test, and the Physical score and the Mental score on the SF-12. This study included a total of 46 adults, 30 females and 16 males, with a mean age of 63.7 ± 10.9 years. HA, PRP-HA, and PBMNCs demonstrated comparable effectiveness for improving the NRS score and all the other outcomes at 6 months. Additionally, PRP-HA and PBMNCs also enhanced knee flexion and the International Knee Documentation Committee score. However, none of the three treatments led to a significant improvement on the 10-meter walking test. No serious adverse effects were reported. In this study, injections of HA, PRP-HA, and PBMNCs all demonstrated positive outcomes for up to 6 months post-treatment in the subjects suffering from knee OA.
膝关节骨关节炎(OA)是成年人中的一种常见病症,会导致膝关节疼痛和功能障碍。在过去二十年中,由于富含血小板血浆(PRP)、透明质酸(HA)以及新型外周血来源单核细胞(PBMNCs)的出现,局部关节内膝关节注射疗法越来越受欢迎。本研究旨在比较关节内注射PBMNCs、HA以及PRP与透明质酸联合制剂(PRP-HA)治疗根据凯尔格伦和劳伦斯(KL)分级为II期和III期的退行性膝关节OA的疗效。这项回顾性观察研究纳入了在意大利卡塔尼亚大学医院接受治疗的中至中度严重膝关节OA的成年人。受试者被分为三组,分别接受关节内注射HA、PRP-HA或PBMNCs治疗。评估的结果指标如下:数字评分量表、西安大略和麦克马斯特大学骨关节炎指数、计时起立行走测试、国际膝关节文献委员会评分、10米步行测试以及SF-12身体评分和心理评分。本研究共纳入46名成年人,其中女性30名,男性16名,平均年龄为63.7±10.9岁。HA、PRP-HA和PBMNCs在改善6个月时的NRS评分和所有其他结果方面显示出相当的有效性。此外,PRP-HA和PBMNCs还改善了膝关节屈曲和国际膝关节文献委员会评分。然而,这三种治疗方法均未使10米步行测试有显著改善。未报告严重不良反应。在本研究中,对于患有膝关节OA的受试者,注射HA、PRP-HA和PBMNCs在治疗后长达6个月均显示出积极效果。